Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Share-based Compensation (2016 - 2026)

Tenax Therapeutics' Share-based Compensation history spans 8 years, with the latest figure at -$79525.0 for Q4 2017.

  • On a quarterly basis, Share-based Compensation fell 39082.84% to -$79525.0 in Q4 2017 year-over-year; TTM through Sep 2017 was $79729.0, a 5007.56% increase, with the full-year FY2025 number at $18.8 million, up 1780.0% from a year prior.
  • Share-based Compensation hit -$79525.0 in Q4 2017 for Tenax Therapeutics, down from $79525.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for TENX hit a ceiling of $397958.0 in Q2 2014 and a floor of -$79525.0 in Q4 2017.
  • Historically, Share-based Compensation has averaged $55978.5 across 5 years, with a median of $703.0 in 2015.
  • The widest YoY moves for Share-based Compensation: up 30486.54% in 2017, down 39082.84% in 2017.
  • Tracing TENX's Share-based Compensation over 5 years: stood at $66916.0 in 2013, then crashed by 77.82% to $14840.0 in 2014, then crashed by 95.26% to $703.0 in 2015, then tumbled by 70.98% to $204.0 in 2016, then plummeted by 39082.84% to -$79525.0 in 2017.
  • Business Quant data shows Share-based Compensation for TENX at -$79525.0 in Q4 2017, $79525.0 in Q2 2017, and $204.0 in Q4 2016.